Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Type 2 diabetes
Biotech
Lilly triple-G bet sees 16.8% weight loss in ph. 3 diabetes test
Eli Lilly is rounding out its pitch for retatrutide with new data looking at blood sugar reductions and weight loss in patients with Type 2 diabetes.
Fraiser Kansteiner
Mar 19, 2026 6:45am
Insulet, Abbott, Dexcom set sights on Type 2 diabetes at ATTD
Mar 12, 2026 1:07pm
Novo’s CagriSema tops semaglutide in ph. 3 diabetes study
Feb 2, 2026 3:01pm
Arrowhead takes aim at obesity with early gene silencing data
Jan 6, 2026 10:19am
GlucoModicum touts needle-free Sofio glucose monitor patch
Dec 18, 2025 2:06pm
Novo expands pivotal program after amycretin shines in diabetes
Nov 25, 2025 7:44am
